PMO Interview with the Innovator Series

Best Practices in Oncology Biomarker Testing

Drs. Goeffrey Oxnard and Lauren Ritterhouse review the best practices to improve efficiencies in biomarker testing, including effective communication among the healthcare team, the pathologist, and the patient, as well as expediting processing in the pathology laboratory.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Creating a Paradigm for Biomarker Testing

Drs. Goeffrey Oxnard and Lauren Ritterhouse consider the advantages and disadvantages of liquid biopsies as an early screening tool for biomarker testing, and how to integrate various approaches into a biomarker testing paradigm.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

The Role of Tumor Mutational Burden in Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Improving Efficiencies in Oncology Biomarker Testing

Drs. Roy Herbst and David Rimm discuss ways in which the time required to complete biomarker testing can be reduced, from obtaining and processing tissues, performing the testing, evaluating results, and reporting results to the cancer care team.

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Dealing with Issues of Obtaining Sufficient Tissue in Performing Biomarker Testing

Drs. Roy Herbst and David Rimm review some of the problems associated with obtaining enough tissue to perform biomarker testing, the need to triage tissue to ensure that standard of care tests are completed, and the potential role of liquid biopsies

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer [ Read More ]

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

The Use of Next-Generation Sequencing in Treating Non-Squamous Non-Small-Cell Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse consider how next-generation sequencing (NGS) informs treatment of lung cancer patients in providing information on tumor mutational burden, microsatellite instability, unique targetable genomic signatures, as well as novel targets that may be best addressed in a clinical trial.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Accurate and Reproducible Measurement of PD-1/PD-L1

Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

How to Foster Communication Among all Members of the Cancer Care Team with Pathologists to Deliver Individualized Treatment for Patients with Lung Cancer

Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12

Sign me up!